• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Datascope joins Maquet countersuit against Abiomed

Datascope joins Maquet countersuit against Abiomed

June 16, 2017 By Fink Densford

Getinge's Maquet, Datascope; Abiomed

Getinge‘s (PINK:GETI B) Datascope said today it is filing a motion to join fellow Getinge company Maquet‘s patent infringement case against Abiomed (NSDQ:ABMD).

The Wayne, N.J.-based company said it is asserting counterclaims which allege that Abiomed engaged in false advertising to promote that its Impella device was superior to Datascope’s intra-aortic balloon pumps.

Datascope said that, simultaneously, Maquet will be expanding the infringement case by alleging that most Impella models infringe upon 3 Maquet patents, bringing the total number of patents in the suit to 6.

In Datascope’s counterclaims, the company asserts that Abiomed “engaged in a pattern of intentional and widespread false advertising regarding Impella compared with IABP in violation of federal and state law,” according to a press release.

In the suit, it is alleged that Abiomed falsely advertised that the Protect II trial and a related “hypothesis-generating” post hoc analysis of data from the trial demonstrated that the Impella significantly reduced major adverse events compared with IABPs.

Datascope added that “recent developments” supported Datascope’s position that Abiomed’s superiority claims were unlawful. The company said that in Health Quality Ontario’s Feb. 2017 in-depth tech assessment concluded that “percutaneous ventricular support with Impella does not lower death rates; nor is it safer or cheaper than usual treatment with balloon pumps,” according to a press release.

The company goes on to allege that Abiomed disseminated false representations regarding the US FDA’s approval of IABP, the cost-effectiveness of it’s Impella compared to IABP, and other features of the Impella device. In the suit, the company claims that Abiomed advertised that IABP was not FDA-approved as safe and effective for treating acute myocardial infarction, cardiogenic shock or for use during high-risk PCI, which Datascope claims is false.

Last July, after being threatened with a patent infringement lawsuit if it didn’t agree to a licensing deal with Maquet, Abiomed responded by asking a Massachusetts judge for a judgment of non-infringement in May 2015.

Maquet sent a letter to Danvers, Mass.-based Abiomed in December 2015, alleging infringement of a trio of patents by the Impella line of transcatheter heart pumps and seeking a licensing deal – and threatening a patent infringement action in the alternative.

In a Jan. 19 response, a lawyer for Abiomed said the Maquet patent claims were “devoid of any merit” and denied any infringement.

Filed Under: Legal News, Patent Infringement Tagged With: Abiomed, Datascope Corp., Getinge, Maquet Cardiovascular LLC

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy